- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Atlas.
Displaying page 1 of 2.
EudraCT Number: 2010-022184-35 | Sponsor Protocol Number: ATLAS | Start Date*: 2011-10-04 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: A pragmatic randomised double-blind trial of Antipsychotic Treatment of very LAte-onset Schizophrenia-like psychosis: The ATLAS Trial | |||||||||||||
Medical condition: late-onset schizophrenia-like psychosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002708-25 | Sponsor Protocol Number: RIVAROXACS3001 (BAY59-7939/13194) | Start Date*: 2008-11-27 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome The ATLAS ACS 2 ... | |||||||||||||
Medical condition: Acute Coronary Syndrome (ACS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) LT (Completed) DE (Completed) PT (Completed) SK (Completed) HU (Completed) FR (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) IT (Completed) LV (Completed) CZ (Completed) BG (Completed) BE (Prematurely Ended) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004449-40 | Sponsor Protocol Number: BAY 59-7939/11898 | Start Date*: 2007-02-02 | |||||||||||
Sponsor Name:Bayer HealthCare AG | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Escalation and Dose-Confirmation Study to Evaluate the Safety and Efficacy of Rivaroxaban in Combination with Aspirin Alone or with... | |||||||||||||
Medical condition: Acute Coronary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) HU (Completed) BE (Completed) NL (Completed) DK (Completed) CZ (Completed) SE (Completed) SK (Completed) GB (Completed) BG (Completed) FI (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000679-18 | Sponsor Protocol Number: EFC15467 | Start Date*: 2019-07-23 | |||||||||||
Sponsor Name:Genzyme Corporation | |||||||||||||
Full Title: ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in male pediatric subjects aged 1 to less than 12 years with hemophilia A or B | |||||||||||||
Medical condition: Hemophilia A or B | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: ES (Restarted) Outside EU/EEA IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003541-11 | Sponsor Protocol Number: BL006 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:UroGen Pharma Ltd. | |||||||||||||
Full Title: A Randomized, Controlled, Open-label Study of the Efficacy, Durability, and Safety of UGN-102 With or Without TURBT in Patients with Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (... | |||||||||||||
Medical condition: Non-Muscle Invasive Bladder Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) BG (Completed) LV (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002159-32 | Sponsor Protocol Number: 211LE201 | Start Date*: 2012-03-30 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of BIIB023 in Subjects With Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Prematurely Ended) BE (Completed) DE (Completed) ES (Prematurely Ended) HU (Completed) IT (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002880-25 | Sponsor Protocol Number: LTE15174 | Start Date*: 2019-03-08 | ||||||||||||||||
Sponsor Name:Genzyme Corporation | ||||||||||||||||||
Full Title: ATLAS-OLE: An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX | ||||||||||||||||||
Medical condition: Hemophilia A or Hemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: IE (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) HU (Trial now transitioned) ES (Prematurely Ended) FR (Trial now transitioned) DK (Trial now transitioned) Outside EU/EEA IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-000744-17 | Sponsor Protocol Number: LONG 05-05 | Start Date*: 2006-03-22 |
Sponsor Name:University Hospital Ghent | ||
Full Title: A randomised phase II study evaluating two schedules of the 21-day regimen of Gemcitabine and Carboplatin in advanced NSCLC | ||
Medical condition: Non-small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001158-33 | Sponsor Protocol Number: OZR-2016-34 | Start Date*: 2017-07-20 |
Sponsor Name:The Rotterdam Eye Hospital | ||
Full Title: A pilot study towards a therapy with prednisolone encapsulated liposomes for the treatment of Graves’ Orbitopathy with reduced systemic steroid exposure | ||
Medical condition: Graves' Orbitopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-004087-19 | Sponsor Protocol Number: ALN-AT3SC-009 | Start Date*: 2017-08-25 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: ATLAS-PPX trial: an open-label, multinational, switching study to describe the efficacy and safety of fitusiran prophylaxis in hemophilia A and B patients previously receiving factor or bypassing a... | ||||||||||||||||||
Medical condition: Hemophilia A or Hemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: ES (Prematurely Ended) IE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) NL (Not Authorised) IT (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004334-99 | Sponsor Protocol Number: 151201 | Start Date*: 2016-02-01 |
Sponsor Name:Department of Endocrinology | ||
Full Title: Treatment of Graves´ ophthalmopathy with diclofenak or simvastatin | ||
Medical condition: Graves´ophthalmopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002946-62 | Sponsor Protocol Number: 207966 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:ViiV Healthcare, S.L. | |||||||||||||
Full Title: A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine A... | |||||||||||||
Medical condition: Human Immunodeficiency Virus type 1 (HIV-1) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) SE (Ongoing) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001464-11 | Sponsor Protocol Number: ALN-AT3SC-004 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: ATLAS-A/B: A Phase 3 study to evaluate the efficacy and safety of fitusiran in patients with hemophilia A or B, without inhibitory antibodies to factor VIII or IX | ||||||||||||||||||
Medical condition: Hemophilia A or Hemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: IE (Prematurely Ended) BG (Completed) HU (Completed) ES (Prematurely Ended) PT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) DK (Completed) NL (Not Authorised) IT (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-003007-38 | Sponsor Protocol Number: 56021927PCR3003 | Start Date*: 2016-01-11 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | |||||||||||||
Medical condition: High- or very-high risk, localized or locally advanced prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BE (Trial now transitioned) NL (Completed) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004590-51 | Sponsor Protocol Number: 233AS303 | Start Date*: 2021-09-15 | |||||||||||||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||||||||||||
Full Title: A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed... | |||||||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) associated with SOD1 gene mutation | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Completed) IT (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001463-36 | Sponsor Protocol Number: EFC14768 | Start Date*: 2018-07-25 | ||||||||||||||||
Sponsor Name:Genzyme Corporation | ||||||||||||||||||
Full Title: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX | ||||||||||||||||||
Medical condition: Hemophilia A or Hemophilia B | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BG (Completed) HU (Completed) ES (Prematurely Ended) PT (Completed) FR (Completed) DE (Completed) DK (Completed) NL (Not Authorised) IT (Prematurely Ended) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-002123-93 | Sponsor Protocol Number: MINGO | Start Date*: 2009-07-30 | |||||||||||
Sponsor Name:Johannes Gutenberg-Universität | |||||||||||||
Full Title: Mycophenolate sodium in Graves’ orbitopathy | |||||||||||||
Medical condition: Graves' orbitopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011273-32 | Sponsor Protocol Number: 149/09 | Start Date*: 2009-05-07 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Pilot study for the evaluation of the safety and the feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in patients on stable treatment with two NRTIs + atazanavir/ritonav... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004641-33 | Sponsor Protocol Number: DIA2020-01 | Start Date*: 2021-02-16 | |||||||||||||||||||||
Sponsor Name:Diakonhjemmet Hospital | |||||||||||||||||||||||
Full Title: The Methotrexate in ERosive INflammatory Osteoarthritis (MERINO) trial | |||||||||||||||||||||||
Medical condition: Norwegian adult males and females with symptomatic erosive inflammatory hand osteoarthritis. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NO (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001060-21 | Sponsor Protocol Number: 374/11 | Start Date*: 2011-10-17 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Safety and efficacy of switching a stable combined antiretroviral therapeutic regimen to atazanavir with ritonavir plus lamivudine in treatment experienced HIV positive patients with full and stabl... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
